These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 25859838)

  • 1. Tumor Lysis Syndrome in Metastatic Colon Cancer Following Treatment with Regorafenib.
    Farooqi B; Simmons J; Hao Z
    J Gastrointest Cancer; 2015 Sep; 46(3):314-6. PubMed ID: 25859838
    [No Abstract]   [Full Text] [Related]  

  • 2. Regorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendations.
    Grothey A
    Clin Adv Hematol Oncol; 2015 Aug; 13(8):514-7. PubMed ID: 26351814
    [No Abstract]   [Full Text] [Related]  

  • 3. Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma.
    Takigawa H; Kitadai Y; Shinagawa K; Yuge R; Higashi Y; Tanaka S; Yasui W; Chayama K
    Cancer Sci; 2016 May; 107(5):601-8. PubMed ID: 26865419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A case of erythema multiforme induced by regorafenib therapy for metastatic colon cancer].
    Mii Y; Fukuoka E; Murata K; Otsubo D; Sawa H; Oka S; Iwatani Y; Kuroda D
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):1841-3. PubMed ID: 25731348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regorafenib suppresses colon tumorigenesis and the generation of drug resistant cancer stem-like cells via modulation of miR-34a associated signaling.
    Cai MH; Xu XG; Yan SL; Sun Z; Ying Y; Wang BK; Tu YX
    J Exp Clin Cancer Res; 2018 Jul; 37(1):151. PubMed ID: 30005681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry.
    Kopeckova K; Buchler T; Bortlicek Z; Hejduk K; Chloupkova R; Melichar B; Pokorna P; Tomasek J; Linke Z; Petruzelka L; Kiss I; Prausova J
    Target Oncol; 2017 Feb; 12(1):89-95. PubMed ID: 27638381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors.
    Myint ZW; Sen JM; Watts NL; Druzgal TJ; Nathan BR; Ward MD; Boyer JE; Fracasso PM
    Clin Colorectal Cancer; 2014 Jun; 13(2):127-30. PubMed ID: 24461491
    [No Abstract]   [Full Text] [Related]  

  • 8. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model.
    Abou-Elkacem L; Arns S; Brix G; Gremse F; Zopf D; Kiessling F; Lederle W
    Mol Cancer Ther; 2013 Jul; 12(7):1322-31. PubMed ID: 23619301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of the Mechanism of Action of Regorafenib for Clinical Practice.
    Prager G
    Clin Adv Hematol Oncol; 2019 Aug; 17 Suppl 12(8):5-13. PubMed ID: 32720933
    [No Abstract]   [Full Text] [Related]  

  • 10. Regorafenib in metastatic colorectal cancer.
    Sartore-Bianchi A; Zeppellini A; Amatu A; Ricotta R; Bencardino K; Siena S
    Expert Rev Anticancer Ther; 2014 Mar; 14(3):255-65. PubMed ID: 24559322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Successful Administration of Regorafenib to a Metastatic Colon Cancer Patient with Impaired Performance Status by Reducing the Initial Dose].
    Nishitai R; Manaka D; Kudo R; Mitsuoka E; Kanai S; Kanto S; Yoshino K; Hamasu SY; Konishi S; Yamashiro Y
    Gan To Kagaku Ryoho; 2015 Jul; 42(7):871-3. PubMed ID: 26197753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regorafenib as a potential adjuvant chemotherapy agent in disseminated small colon cancer: Drug selection outcome of a novel screening system using nanoimprinting 3-dimensional culture with HCT116-RFP cells.
    Yoshii Y; Furukawa T; Aoyama H; Adachi N; Zhang MR; Wakizaka H; Fujibayashi Y; Saga T
    Int J Oncol; 2016 Apr; 48(4):1477-84. PubMed ID: 26820693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The malignant progression effects of regorafenib in human colon cancer cells.
    Tomida C; Aibara K; Yamagishi N; Yano C; Nagano H; Abe T; Ohno A; Hirasaka K; Nikawa T; Teshima-Kondo S
    J Med Invest; 2015; 62(3-4):195-8. PubMed ID: 26399347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life study.
    Del Prete S; Cennamo G; Leo L; Montella L; Vincenzi B; Biglietto M; Andreozzi F; Prudente A; Iodice P; Savastano C; Nappi A; Montesarchio V; Addeo R
    Future Oncol; 2017 Feb; 13(5):415-423. PubMed ID: 27780365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal perforation during regorafenib administration in a case with hepatic metastases of colon cancer.
    Ogata K; Takamori H; Umezaki N; Yagi T; Ogawa K; Ozaki N; Hayashi H; Tanaka H; Ikuta Y; Doi K
    J Chemother; 2017 Oct; 29(5):314-316. PubMed ID: 27438692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib.
    Lim Y; Bang JI; Han SW; Paeng JC; Lee KH; Kim JH; Kang GH; Jeong SY; Park KJ; Kim TY
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):757-764. PubMed ID: 27888325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regorafenib in metastatic colorectal cancer.
    Grothey A
    Clin Adv Hematol Oncol; 2012 May; 10(5):324-5. PubMed ID: 22706543
    [No Abstract]   [Full Text] [Related]  

  • 18. Monitoring Cell Death in Regorafenib-Treated Experimental Colon Carcinomas Using Annexin-Based Optical Fluorescence Imaging Validated by Perfusion MRI.
    Kazmierczak PM; Burian E; Eschbach R; Hirner-Eppeneder H; Moser M; Havla L; Eisenblätter M; Reiser MF; Nikolaou K; Cyran CC
    PLoS One; 2015; 10(9):e0138452. PubMed ID: 26393949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How translational research can guide the use of regorafenib in patients with metastatic colorectal cancer.
    Prager GW
    Clin Adv Hematol Oncol; 2020 Jan; 18 Suppl 2(1):18-21. PubMed ID: 33843907
    [No Abstract]   [Full Text] [Related]  

  • 20. Angiopoietin-2/Tie2 Inhibition by Regorafenib Associates With Striking Response in a Patient With Aggressive Hepatocellular Carcinoma.
    Todesca P; Marzi L; Critelli RM; Cuffari B; Caporali C; Turco L; Pinelli G; Schepis F; Carulli L; de Maria N; Casari F; Scaglioni R; Villa E
    Hepatology; 2019 Aug; 70(2):745-747. PubMed ID: 30802985
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.